ERBB2 and breast cancer: On comparing the differences in clinicopathological characteristics between the two risk groups (Supplementary Table S1), the high-risk group was found to have more patients with T4 stage, ER-negative, PR-negative and HER2-positive breast cancers and more patients in the post-menopausal status.